Publicaciones en colaboración con investigadores/as de University of Amsterdam (17)

2024

  1. Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    Schizophrenia, Vol. 10, Núm. 1

2023

  1. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  2. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  3. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Neuroscience and Biobehavioral Reviews, Vol. 149

  4. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  2. Migration history and risk of psychosis: Results from the multinational EU-GEI study

    Psychological Medicine, Vol. 52, Núm. 14, pp. 2972-2984

2021

  1. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders

    JAMA Psychiatry, Vol. 78, Núm. 1, pp. 47-63

2020

  1. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia

    Nature Neuroscience, Vol. 23, Núm. 2, pp. 179-184

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

    Nature Communications, Vol. 10, Núm. 1

  2. Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE)

    Psychological Medicine, Vol. 49, Núm. 15, pp. 2600-2607

  3. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

    The Lancet Psychiatry, Vol. 6, Núm. 5, pp. 427-436

2018

  1. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2014

  1. Identifying gene-environment interactions in schizophrenia: Contemporary challenges for integrated, large-scale investigations

    Schizophrenia Bulletin, Vol. 40, Núm. 4, pp. 729-736